BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15990221)

  • 1. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment.
    Josefsson A; Wikström P; Granfors T; Egevad L; Karlberg L; Stattin P; Bergh A
    Eur Urol; 2005 Oct; 48(4):577-83. PubMed ID: 15990221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
    Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
    Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer.
    Fowler CJ; Josefsson A; Thors L; Chung SC; Hammarsten P; Wikström P; Bergh A
    Biochim Biophys Acta; 2013 Oct; 1831(10):1579-87. PubMed ID: 23262399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
    Wikström P; Lissbrant IF; Stattin P; Egevad L; Bergh A
    Prostate; 2002 Jun; 51(4):268-75. PubMed ID: 11987155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of neovasculature in uveal melanoma by targeting the TGFbeta-binding receptor endoglin: is there prognostic relevance of proliferating endothelium?
    Ziemssen F; Wegner R; Wegner J; Tatar O; Süsskind D; Gelisken F; Rohrbach M; Bartz-Schmidt KU; Grisanti S
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1124-31. PubMed ID: 16523306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the Gleason score in prostate cancer.
    Egevad L; Granfors T; Karlberg L; Bergh A; Stattin P
    BJU Int; 2002 Apr; 89(6):538-42. PubMed ID: 11942960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
    El-Gohary YM; Silverman JF; Olson PR; Liu YL; Cohen JK; Miller R; Saad RS
    Am J Clin Pathol; 2007 Apr; 127(4):572-9. PubMed ID: 17369132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
    Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
    Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
    Tidehag V; Hammarsten P; Egevad L; Granfors T; Stattin P; Leanderson T; Wikström P; Josefsson A; Hägglöf C; Bergh A
    Eur J Cancer; 2014 Jul; 50(10):1829-1835. PubMed ID: 24726733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer.
    Lind AJ; Wikström P; Granfors T; Egevad L; Stattin P; Bergh A
    Prostate; 2005 Mar; 62(4):394-9. PubMed ID: 15378518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.
    Egevad L; Granfors T; Karlberg L; Bergh A; Stattin P
    J Urol; 2002 Aug; 168(2):509-13. PubMed ID: 12131299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
    Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
    Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
    Tolonen TT; Tammela TL; Kujala PM; Tuominen VJ; Isola JJ; Visakorpi T
    BJU Int; 2011 Nov; 108(9):1430-8. PubMed ID: 21592298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
    Roach M; Weinberg V; Sandler H; Thompson I
    Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Incidence of Incidental Prostate Cancer in Transurethral Resection of Prostate Specimens in China. The Value of Pathologic Review.
    Lin J; Yu X; Yang X; Jin J; Zhou L; Liu L; Su J; Li Y; Shang M
    Anal Quant Cytopathol Histpathol; 2016 Feb; 38(1):31-7. PubMed ID: 27363064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of Gleason scores in metastatic prostate cancer.
    Rusthoven CG; Carlson JA; Waxweiler TV; Yeh N; Raben D; Flaig TW; Kavanagh BD
    Urol Oncol; 2014 Jul; 32(5):707-13. PubMed ID: 24629494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
    Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.